B-type natriuretic peptide plasma levels are elevated in subcortical vascular dementia

Kondziella, Daniel; Göthlin, Mattias; Fu, Michael; Zetterberg, Henrik; Wallin, Anders

doi:10.1097/wnr.0b013e328326f82f

Cited by 29 publications

(31 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12 In that study, BNP levels were predictive of cognitive function in 56 older adults with a history of cardiovascular disease. A second study found that BNP levels were associated with vascular dementia but not Alzheimer’s disease, 27 though more recently Buerger et al found that NP levels were associated with progression from mild cognitive impairment to clinical Alzheimer’s disease. 28 Our results are the first to show that NP levels are associated with poor cognitive function even among community-dwelling individuals unselected for cardiovascular disease.…”

Section: Discussionmentioning

confidence: 97%

Elevated Natriuretic Peptide Levels and Cognitive Function in Community-dwelling Older Adults

Daniels

Laughlin

Kritz‐Silverstein

et al. 2011

The American Journal of Medicine

View full text Add to dashboard Cite

Background Natriuretic peptides (NP’s) have prognostic value across a wide spectrum of cardiovascular diseases and may predict cognitive dysfunction in patients with cardiovascular disease even in the absence of prior stroke. Little is known about the association of NP’s with cognitive function in community-dwelling adults. We assessed the association between NT-proBNP levels and cognitive function in community-dwelling ambulatory older adults in the Rancho Bernardo Study. Methods We studied 950 men and women, aged 60 years and older, who attended a research clinic visit where a medical history and examination were performed, and blood for cardiovascular disease risk factors and NT-proBNP levels were obtained. Three cognitive function tests were administered: Mini Mental State Exam (MMSE), Trail-Making Test B (Trails B), and Category Fluency. Results Participants with high NT-proBNP levels (≥450 pg/mL, n=198) were older and had a higher prevalence of coronary heart disease (12% vs. 30%), and stroke (5% vs. 11%) (both p’s≤0.001). In unadjusted analyses, all three cognitive function test scores were significantly associated with NT-proBNP levels (p<0.001). After adjusting for age, sex, education, hypertension, body mass index, exercise, alcohol use, smoking, low density lipoprotein cholesterol, creatinine clearance, and prior cardiovascular disease, elevated NT-proBNP levels remained independently associated with poor cognitive performance on MMSE (odds ratio [95% confidence interval] 2.0 [1.1–3.6], p=0.02) and Trails B (1.7 [1.2–2.7], p=0.01), but not Category Fluency (1.4 [0.9–2.2], p=0.19). Results were unchanged after excluding the 6% of participants with a history of stroke. Conclusions NT-proBNP levels were strongly and independently associated with poor cognitive function in community-dwelling older adults.

show abstract

Section: Discussionmentioning

confidence: 97%

Elevated Natriuretic Peptide Levels and Cognitive Function in Community-dwelling Older Adults

Daniels

Laughlin

Kritz‐Silverstein

et al. 2011

The American Journal of Medicine

View full text Add to dashboard Cite

show abstract

“…Even though it is not known whether plasma BNP levels in the current study reflect brain or cardiac origin, CSF levels of BNP are significantly lower compared with plasma levels, suggesting that much or most plasma BNP is not brain derived. 51 Another marker identified in this study, SGOT (also known as aspartate transaminase), is typically associated with liver or skeletal muscle injury. SGOT levels were found to be lower in AD patients relative to control or MCI patients and showed significance (uncorrected for multiple comparisons) in the univariate and the multivariate analysis.…”

Section: Discussionmentioning

confidence: 98%

Evaluation of Plasma Proteomic Data for Alzheimer Disease State Classification and for the Prediction of Progression From Mild Cognitive Impairment to Alzheimer Disease

Llano

Devanarayan

Simon³

2013

Alzheimer Disease &Amp; Associated Disorders

View full text Add to dashboard Cite

Previous studies that have examined the potential for plasma markers to serve as biomarkers for Alzheimer disease (AD) have studied single analytes and focused on the amyloid-β and τ isoforms and have failed to yield conclusive results. In this study, we performed a multivariate analysis of 146 plasma analytes (the Human DiscoveryMAP v 1.0 from Rules-Based Medicine) in 527 subjects with AD, mild cognitive impairment (MCI), or cognitively normal elderly subjects from the Alzheimer's Disease Neuroimaging Initiative database. We identified 4 different proteomic signatures, each using 5 to 14 analytes, that differentiate AD from control patients with sensitivity and specificity ranging from 74% to 85%. Five analytes were common to all 4 signatures: apolipoprotein A-II, apolipoprotein E, serum glutamic oxaloacetic transaminase, α-1-microglobulin, and brain natriuretic peptide. None of the signatures adequately predicted progression from MCI to AD over a 12- and 24-month period. A new panel of analytes, optimized to predict MCI to AD conversion, was able to provide 55% to 60% predictive accuracy. These data suggest that a simple panel of plasma analytes may provide an adjunctive tool to differentiate AD from controls, may provide mechanistic insights to the etiology of AD, but cannot adequately predict MCI to AD conversion.

show abstract

“…Similarly, cardiac troponin T is a very sensitive and specific indicator of myocardial damage. A few studies report that serum levels of BNP [141, 142] or cardiac troponin T [143] are elevated in VCI-SSVD. These results need to be substantiated by other investigations to propose these molecules as relevant biomarkers for VCI-SSVD.…”

Section: Methodsmentioning

confidence: 99%

Biochemical markers in vascular cognitive impairment associated with subcortical small vessel disease - A consensus report

et al. 2017

View full text Add to dashboard Cite

BackgroundVascular cognitive impairment (VCI) is a heterogeneous entity with multiple aetiologies, all linked to underlying vascular disease. Among these, VCI related to subcortical small vessel disease (SSVD) is emerging as a major homogeneous subtype. Its progressive course raises the need for biomarker identification and/or development for adequate therapeutic interventions to be tested. In order to shed light in the current status on biochemical markers for VCI-SSVD, experts in field reviewed the recent evidence and literature data.MethodThe group conducted a comprehensive search on Medline, PubMed and Embase databases for studies published until 15.01.2017. The proposal on current status of biochemical markers in VCI-SSVD was reviewed by all co-authors and the draft was repeatedly circulated and discussed before it was finalized.ResultsThis review identifies a large number of biochemical markers derived from CSF and blood. There is a considerable overlap of VCI-SSVD clinical symptoms with those of Alzheimer’s disease (AD). Although most of the published studies are small and their findings remain to be replicated in larger cohorts, several biomarkers have shown promise in separating VCI-SSVD from AD. These promising biomarkers are closely linked to underlying SSVD pathophysiology, namely disruption of blood-CSF and blood–brain barriers (BCB-BBB) and breakdown of white matter myelinated fibres and extracellular matrix, as well as blood and brain inflammation. The leading biomarker candidates are: elevated CSF/blood albumin ratio, which reflects BCB/BBB disruption; altered CSF matrix metalloproteinases, reflecting extracellular matrix breakdown; CSF neurofilment as a marker of axonal damage, and possibly blood inflammatory cytokines and adhesion molecules. The suggested SSVD biomarker deviations contrasts the characteristic CSF profile in AD, i.e. depletion of amyloid beta peptide and increased phosphorylated and total tau.ConclusionsCombining SSVD and AD biomarkers may provide a powerful tool to identify with greater precision appropriate patients for clinical trials of more homogeneous dementia populations. Thereby, biomarkers might promote therapeutic progress not only in VCI-SSVD, but also in AD.

show abstract

B-type natriuretic peptide plasma levels are elevated in subcortical vascular dementia

Cited by 29 publications

References 19 publications

Elevated Natriuretic Peptide Levels and Cognitive Function in Community-dwelling Older Adults

Elevated Natriuretic Peptide Levels and Cognitive Function in Community-dwelling Older Adults

Evaluation of Plasma Proteomic Data for Alzheimer Disease State Classification and for the Prediction of Progression From Mild Cognitive Impairment to Alzheimer Disease

Biochemical markers in vascular cognitive impairment associated with subcortical small vessel disease - A consensus report

Contact Info

Product

Resources

About